You are here:

Archived: Nicotinic acid modified release tablet (Niaspan®)

Advice

Following a full resubmission.

Nicotinic acid modified release tablets (Niaspan®) is not recommended for use in NHS Scotland for the treatment of dyslipidaemia and primary hypercholesterolaemia as monotherapy in patients who do not tolerate HMG-CoA reductase inhibitors and is not recommended for use when prescribed in combination with HMG-CoA reductase inhibitors (statins).

There is evidence that nicotinic acid modified release tablets lowers LDL cholesterol levels to a small extent and raises HDL-cholesterol levels to a greater extent. However the evidence for use in combination with HMG-CoA reductase inhibitors is less convincing. The economic case for use as monotherapy or co-therapy in the licensed indication was not demonstrated.

Drug Details

Drug Name: Nicotinic acid modified release tablet (Niaspan®)
SMC Drug ID: 93/04
Manufacturer: Merck Serono Ltd
Indication: Dyslipidaemia
BNF Category:
Sub Category: 2.12 Lipid-regulating drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 10 January 2005

Current Advice

Resubmission 13 February 2006

Archived Advice

Full submission 13 April 2004

Back